On August 4, 2022, the Department of Health and Human Services (HHS) issued a proposed rule on Section 1557 (first finalized in May 2016) of the Affordable Care Act (ACA), which prohibits discrimination on the basis of race, color, national origin, sex, age, or disability in certain health programs and activities. This proposal affirms that Section 1557’s prohibition on sex discrimination includes discrimination on the basis of sex stereotypes, sexual orientation, gender identity and sex characteristics, including intersex traits.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
On September 30, 2022, the Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
As expected in the lead-up to midterm elections, Congress today (September 30) passed a continuing resolution (CR) that funds the government through December 16, 2022, avoiding a government shutdown and giving Congress more time to negotiate critical funding decisions for Fiscal Year 2023.
The Centers for Medicare & Medicaid Services (CMS) has extended the deadline to apply for the Enhancing Oncology Model (EOM) to October 10, 2022 at 11:59 p.m. ET.
On October 6, 2022, the definition of information blocking is expanding to include the entire scope of the definition of Electronic Health Information (EHI)—including, electronic protected health information (ePHI) that is or would be in a Designated Record Set (DSR). Practices may want to review and assess their information blocking compliance policies and procedures and contact their EHR vendors to find out how they are preparing to assist practices in meeting the deadline.
In comments to the Centers for Medicare & Medicaid Services (CMS) on the 2023 Hospital Outpatient Prospective Payment System (OPPS) proposed rule, the Association for Clinical Oncology (ASCO) continues to call for a final rule that supports patient access to high-quality, equitable cancer care and support for oncology providers. Highlights from ASCO’s comments are includeded here.
In a step towards addressing one of multiple pending Medicare physician payment cuts, Representatives Ami Bera, MD (D-CA) and Larry Bucshon, MD (R-IN) introduced the Supporting Medicare Providers Act (H.R. 8800), which would increase the conversion factor to 4.42%, effectively putting the Medicare physician fee schedule cut on hold for a year. The new legislation also includes language that says lawmakers and the Department of Health and Human Services should work to promote and reward value-based care, as well as safeguard timely access to high-quality care by advancing health equity and reducing disparities. The Association for Clinical Oncology supports this effort to provide short-term stability and urges Congress to pass the bill before the end of the year.
The American Society of Clinical Oncology (ASCO) released a new frequently asked questions (FAQs) document on the safe handling of hazardous drugs, including those used to treat individuals with cancer, as a resource for its members. The FAQ document focuses on the current hazardous drug safe handling standards from the United States Pharmacopeia (USP), the National Institute for Occupational Safety and Health (NIOSH), and the Occupational Safety and Health Administration (OSHA). The document also highlights ASCO’s work for the oncology community on the issue, including its own standards for the safe handling of hazardous drugs, which were released in early 2019.
On September 21, 2022, the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
On September 21, 2022, the Food and Drug Administration granted regular approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.
On September 20, 2022, the Food and Drug Administration approved sodium thiosulfate (Pedmark, Fennec Pharmaceuticals Inc.) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors.
A new study, published today in JCO Oncology Practice, finds that oncologists have different perspectives on how to select starting doses for patients with metastatic cancer. The study shares findings from a 2021 international survey of 367 medical oncologists who treat patients with metastatic breast or gastrointestinal (GI) cancers.
UPDATE: On September 14, 2022, the House of Representatives passed the Improving Seniors’ Timely Access to Care Act (H.R. 3173) by voice vote on the House floor. The bill now moves to the Senate. This remains a critical moment when your Senators need to hear your support for this legislation. Please ask them to pass this bill into law—it takes seconds using the ACT Network.
The American Society of Clinical Oncology (ASCO) issued a new position statement on Medicare billing for split or shared (split/shared) evaluation and management (E/M) services. The statement summarizes ASCO’s concerns about changes to split/shared E/M services and makes recommendations to better align Medicare coding for E/M services with the care that beneficiaries with cancer need.